In Barrett's esophagus, the normal ...

In Barrett's esophagus, the normal squamous lining of the distal esophagus is replaced with a metaplastic, intestinal, columnar epithelium. Barrett's esophagus give an account ofs the end stage of relentless uncontrolled gastroesophageal reflux disease (GERD) However, Barrett's esophagus also is recognized as a precursor for principally cases of esophageal adenocarcinoma. (1)

With the novel increase in the incidence of esophageal adenocarcinoma and its association with GERD endoscopic screening for Barrett's esophagus has been hinted in the hope of decreasing the morbidity and mortality associated with this cancer, as described by dint of Shalauta and Saad (2) in this issue of American Family Physician. While the risk of developing esophageal cancer is relatively small in the general population, the risk for a [i]role[/i] with Barrett's esophagus is long greater.

The literature allows us to make the following assumptions with more [i]or[/i] less degree of certainty: (1) 10 to 20 percent of adults in the United States have reflux; (2) about 10 percent of patients with ebb have Barrett's esophagus; and (3) about 5 to 10 percent of patients with Barrett's esophagus eventually lay open cancer. Given these suppositions, the lake of patients requiring surveillance endoscopy and biopsy for Barrett's esophagus may range from 05 to 2 percent of the adult population. (3)

The diagnosis of Barrett's esophagus requires systematic biopsy of esophageal mucosa with abnormal appearance to discover the presence of specialized intestinal metaplasia. Endoscopy should not be performed for this indication without the ability and intent to obtain appropriate histologic samples of lesions. All areas that are abnormal in appearance should be sampled, and longer portions of Barrett's esophagus should be biopsied each 2 cm.

The routine biopsy of a squamocolumnar junction of normal appearance should be discouraged because intestinal metaplasia not within the esophagus does not assume to have the same premalignant potential. (4) The endoscopist must carefully document the location of the biopsies and clearly communicate this information to the pathologist.

Which patients with GERD should have upper endoscopy? Heartburn and regurgitation are fairly specific symptoms of GERD and chiefly patients with GERD can be managed empirically without endoscopy. Endoscopy is indicated to evaluate the so-called alarm symptoms (i.e., dysphagia, odynophagia, bleeding, and weight loss) and to disguise for Barrett's esophagus. (5) The epidemiology of Barrett's esophagus is not completely understood, however the risk seems to be higher in patients with long-term symptoms, especially white men any researchers have suggested a one-time screening endoscopy in all patients with chronic GERD while others have limited this screening recommendation to patients older than 40 to 50 years who have had GERD symptoms for at least five years. All authorities would address long-term, evidence-based data on which to base clinical recommendations; however, these data will not be available for many years.

popularly clinical practice should be based in succession the imperfect data that are available. The original American literary institution [i]or[/i] seminary of learning of Gastroenterology Practice Guidelines of the Diagnosis Surveillance and Therapy of Barrett's Esophagus (6) commended that patients with longstanding GERD symptoms, particularly patients 50 years or older have upper endoscopy to discover Barrett's esophagus. The more novel guideline was a bit more vague moreover continued to advocate for screening endoscopy in patients with chronic GERD symptoms. (7)

Where does this leave us when trying to determine which patients to sieve for Barrett's esophagus? A patient younger than 40 years with mild, infrequent symptoms may be managed without endoscopy. We must remember that we have no data showing that symptom-driven treatment debars the development of Barrett's esophagus and, therefore, flat these patients eventually may require screening as they age and their duration of acid prospect increases. Most patients with heartburn who are older than 40 to 50 years have chronic symptoms, and it is not unreasonable to defence them (especially white men), regardless of the severity of their symptoms. Patients who initially not away with chronic symptoms (i.e., more than five years) and those who have been followed for several years with ebb symptoms might be included in this group

Furthermore, patients older than 65 years with new-onset GERD symptoms probably should have early endoscopy because their symptoms are les specific and mucosal disease repeatedly is more severe in this age assign places to (8) Finally, there is no ne to withhold therapy while waiting for endoscopy. Although not prov in clinical trials, treating a patient before endoscopy is performed may increase the ability of the endoscopist to recognize Barrett's esophagus and may decrease the risk of a biopsy showing false dysplasia that is actually caused by way of acid-induced inflammation.

Aggressive use of endoscopy would mean that principally patients with GERD would be scop eventually, which would offer economic pressure on the health care hypothesis We can help in limiting the outlay of this approach by avoiding inappropriate repeated screening in patients who have already had negative endoscopy proceeds Most clinicians think that formerly Barrett's esophagus has been exclud with a single endoscopy, the risk of that patient subsequently developing Barrett's esophagus is gentle enough to exclude further screening (probably in the patient's lifetime). Adhering to passing from hand to hand guidelines that have expanded the screening interval for nondysplastic Barrett's esophagus to three years also is important. (6) The price savings from appropriate use of surveillance would help to shoot the cost of screening a larger portion of the population, just as has been advocated in colon cancer screening.